What did @letstrythisagainpodcast actually say?
The creator, who has PCOS and used semaglutide for years, argues that Ozempic is a "band-aid" that never addressed her real problems: overeating, lack of discipline, and poor food choices. She says she "could eat McDonald's every day on Ozempic and still be skinny" and that the medication blocked her personal growth rather than enabling it.
To be clear about what she's claiming: GLP-1 medications don't fix the behavioral and psychological roots of obesity or disordered eating. Stopping them without building those habits means nothing has actually changed. That's her argument, and it's worth engaging with seriously, not dismissing.
She also makes a sharper claim, that people who use these medications for insulin regulation still "have no self-control, insulin or not." That one deserves more scrutiny.
Does the science back this up?
Partially, yes. The rebound data is real and well-documented. But the framing that obesity is fundamentally a discipline problem contradicts the current scientific consensus, and that part matters.
The STEP 1 trial extension (Wilding et al., 2022, New England Journal of Medicine) found that participants regained roughly two-thirds of lost weight within a year of stopping semaglutide. That supports the creator's point that the medication doesn't produce permanent change on its own. Most clinical guidelines now describe GLP-1 therapy as long-term or indefinite for this reason.
However, semaglutide doesn't work by suppressing willpower. It acts on GLP-1 receptors in the brain and gut, reducing appetite signals and slowing gastric emptying. Research by Friedman (2019, Nature Medicine) and others has established that hunger and satiety are largely regulated by hormones and neurological pathways, not character. Calling obesity a "no discipline" problem is a reductive reading of a complex metabolic condition. Especially for someone with PCOS, which directly disrupts insulin sensitivity and hunger regulation.
What did they get wrong (or right)?
She got the rebound risk right. She got the personal experience right. She got the framing of obesity as a moral failure wrong.
The claim that people who use GLP-1s for insulin resistance "still have no self-control" is where this video does real harm. PCOS-related insulin dysregulation isn't a willpower deficiency. It's a documented endocrine disorder. Semaglutide's effects on insulin sensitivity in PCOS patients have been studied specifically, with Jensterle et al. (2022, Journal of Clinical Endocrinology and Metabolism) showing meaningful metabolic improvements beyond weight loss alone.
She's also correct that GLP-1 medications work best alongside behavioral change. A 2021 Diabetes Care meta-analysis found that combining semaglutide with structured lifestyle intervention produced better outcomes than medication alone. That supports her broader point. But "works better with lifestyle change" is not the same as "is just a band-aid that masks symptoms."
- What she got right: Weight regain after stopping is real and clinically documented.
- What she got right: Behavioral patterns matter and medication alone isn't sufficient for everyone.
- What she got wrong: Obesity and insulin resistance are not primarily discipline failures.
- What she got wrong: Her personal experience with semaglutide does not generalize to all patients, particularly those with significant metabolic disease.
What should you actually know?
GLP-1 medications are not shortcuts. They are pharmacological tools that work on real biological mechanisms. For many patients, especially those with type 2 diabetes, severe obesity, or PCOS-related metabolic dysfunction, they represent a medically appropriate intervention, not a character bypass.
That said, the creator raises a legitimate point about the gaps in how these medications are prescribed and supported. If someone is on semaglutide for years without any conversation about nutrition, behavioral health, or what happens when they stop, that's a failure of care, not proof that the medication is inherently a band-aid.
The research on long-term GLP-1 use is still maturing. The SELECT trial (Lincoff et al., 2023, New England Journal of Medicine) showed cardiovascular mortality benefits from semaglutide in high-risk patients that go beyond weight loss, which complicates any simple "it's just cosmetic" narrative.
If you're on a GLP-1 medication and wondering whether you should stop because you haven't done enough "inner work," talk to your prescriber first. Stopping abruptly without a plan, particularly if you have diabetes or PCOS, carries real clinical risk that no podcast episode should be making decisions for you about.